title: A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals.
abstract: OBJECTIVE
  Maraviroc (MVC) is the first approved CCR5 antagonist. The aim of this study was to explore the cost-effectiveness of MVC in treatment-experienced or treatment-resistant HIV-infected adults.
  
  
  METHODS
  The validated HIV microsimulation model ARAMIS was used to predict clinical and economic outcomes of treating patients with optimized background therapy (OBT) alone, as compared to a strategy of testing for the patient's viral tropism and treating with OBT with or without (+/-) MVC in a cohort corresponding to the MOTIVATE screening cohort.
  
  
  RESULTS
  Compared to treatment with OBT alone, a treatment strategy of OBT +/- MVC (twice daily) according to tropism test result was predicted to increase CD4+ cell count after 5 years (from mean 249 to 360 cells/microL), undiscounted life expectancy (7.6 to 8.9 years), and quality-adjusted life years (QALYs; from 4.99 to 5.71) for an additional $40,500, giving an incremental cost-effectiveness ratio of $56,400 per QALY gained. The result was relatively insensitive to alternative clinical and cost assumptions within reasonable ranges, but for individuals with HIV susceptible to only two or fewer components of OBT, the ICER decreased to $52,000 per QALY gained.
  
  
  CONCLUSIONS
  MVC is cost-effective, especially among individuals with few remaining options for active antiretroviral therapy.
authors.affiliation: Health Economics and Outcomes Research, i3 Innovus, Uxbridge, United Kingdom.
authors.forename: Felicitas C
authors.initials: FC
authors.lastname: Kühne
authors.forename: Jeremy
authors.initials: J
authors.lastname: Chancellor
authors.forename: Patrick
authors.initials: P
authors.lastname: Mollon
authors.forename: Daniela E
authors.initials: DE
authors.lastname: Myers
authors.forename: Michael
authors.initials: M
authors.lastname: Louie
authors.forename: William G
authors.initials: WG
authors.lastname: Powderly
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000191:economics / Q000821:virology; D019380:Anti-HIV Agents / Q000191:economics* / Q000627:therapeutic use; D065100:CCR5 Receptor Antagonists; D018791:CD4 Lymphocyte Count; D003362:Cost-Benefit Analysis; D003510:Cyclohexanes / Q000191:economics* / Q000627:therapeutic use; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D005260:Female; D023581:HIV Fusion Inhibitors / Q000191:economics* / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy* / Q000191:economics / Q000821:virology; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D008297:Male; D000077592:Maraviroc; D008875:Middle Aged; D018803:Models, Economic; D009010:Monte Carlo Method; D019057:Quality-Adjusted Life Years; D014230:Triazoles / Q000191:economics* / Q000627:therapeutic use; D056189:Viral Tropism
chemical_list: D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D023581:HIV Fusion Inhibitors; D014230:Triazoles; D000077592:Maraviroc